Loading
PanTher Therapeutics makes absorbable patches that release chemotherapy directly at the tumour over a long period. Its first product, PTM-101, which contains paclitaxel, is in an early trial alongside standard treatment before surgery for pancreatic cancer.
PanTher Therapeutics, Inc., with offices in Austin, Texas, and Watertown, Massachusetts, develops long-lasting, high-dose local chemotherapy products on its Sagittari platform, designed to deliver drug continuously at the tumour site. Its lead, PTM-101, is described in the registry as an absorbable drug product containing paclitaxel, tested as an adjunct to neoadjuvant therapy in treatment-naive borderline resectable and locally advanced pancreatic ductal adenocarcinoma in a phase 1b study (NCT06673017) with US and Australian sites; the company reported completing its first cohort in September 2025 and dose escalation in May 2026. The company lists a USD 1.8 million supplemental award from the Cancer Prevention and Research Institute of Texas in May 2026. Its first registered cancer trial, NCT06673017, was posted on ClinicalTrials.gov in November 2024.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/